Above 40% of Polish children and young adults with type 1 diabetes achieve international HbA1c target - results of a nationwide cross-sectional evaluation of glycemic control: The PolPeDiab HbA1c study.
children
diabetes control
glycated hemoglobin
type 1 diabetes
young adults
Journal
Pediatric diabetes
ISSN: 1399-5448
Titre abrégé: Pediatr Diabetes
Pays: Denmark
ID NLM: 100939345
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
26
05
2021
accepted:
21
06
2021
pubmed:
6
8
2021
medline:
4
2
2022
entrez:
5
8
2021
Statut:
ppublish
Résumé
Youth with type 1 diabetes (T1D) (16-18 y.o.) present worst disease control of all age groups and need structured interventions. Those should be based on unbiased, national-scale outcomes, which have not yet been successfully assessed in Poland. To evaluate the glycemic control in young patients with T1D in Poland. All pediatric diabetes care centers and the nine largest centers for adults with T1D were invited to this cross-sectional study, conducted in March 2018. Eligibility was defined as age ≤ 30 years and diabetes duration ≥1 year. Blinded samples of capillary blood and clinical questionnaires were sent to coordinating center, where HbA1c was measured by high-pressure liquid chromatography. Nine adult and 25/28 pediatric centers participated, providing data for 1255 patients (50.8% males), mean age 12.3 years (95%CI:12.1-12.6) for children and 23.2 years (22.9-23.6) for adults; mean diabetes duration 7.1 years (6.8-7.3). This covered ~8% of pediatric population and 2% of 18-30-years-olds with T1D. Mean HbA1c was comparable between children and adults (57 mmol/mol [7.4%], 95%CI:56-57 mmol/mol [7.3-7.4%] vs. 57 mmol/mol [7.4%], 95%CI:56-60 mmol/mol [7.3-7.6%], p = 0.1870). Overall, 45.2% of patients achieved ISPAD target (<53 mmol/mol [<7.0%]). During the month preceding the study, 0.9% of patients experienced severe hypoglycemia and 0.4% suffered ketoacidosis. HbA1c was related to the method of insulin therapy, continuous glucose monitoring use and body weight (p < 0.0001). In Polish children and young adults with T1D glycemic control expressed as HbA1c is promising in the light of ISPAD guidelines. Our results confirm the known associations between better glycemic control and the use of new technologies and maintaining optimal body weight.
Sections du résumé
BACKGROUND
Youth with type 1 diabetes (T1D) (16-18 y.o.) present worst disease control of all age groups and need structured interventions. Those should be based on unbiased, national-scale outcomes, which have not yet been successfully assessed in Poland.
OBJECTIVE
To evaluate the glycemic control in young patients with T1D in Poland.
METHOD
All pediatric diabetes care centers and the nine largest centers for adults with T1D were invited to this cross-sectional study, conducted in March 2018. Eligibility was defined as age ≤ 30 years and diabetes duration ≥1 year. Blinded samples of capillary blood and clinical questionnaires were sent to coordinating center, where HbA1c was measured by high-pressure liquid chromatography.
RESULTS
Nine adult and 25/28 pediatric centers participated, providing data for 1255 patients (50.8% males), mean age 12.3 years (95%CI:12.1-12.6) for children and 23.2 years (22.9-23.6) for adults; mean diabetes duration 7.1 years (6.8-7.3). This covered ~8% of pediatric population and 2% of 18-30-years-olds with T1D. Mean HbA1c was comparable between children and adults (57 mmol/mol [7.4%], 95%CI:56-57 mmol/mol [7.3-7.4%] vs. 57 mmol/mol [7.4%], 95%CI:56-60 mmol/mol [7.3-7.6%], p = 0.1870). Overall, 45.2% of patients achieved ISPAD target (<53 mmol/mol [<7.0%]). During the month preceding the study, 0.9% of patients experienced severe hypoglycemia and 0.4% suffered ketoacidosis. HbA1c was related to the method of insulin therapy, continuous glucose monitoring use and body weight (p < 0.0001).
CONCLUSIONS
In Polish children and young adults with T1D glycemic control expressed as HbA1c is promising in the light of ISPAD guidelines. Our results confirm the known associations between better glycemic control and the use of new technologies and maintaining optimal body weight.
Substances chimiques
Glycated Hemoglobin A
0
Insulin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1003-1013Investigateurs
Adamska Agnieszka
(A)
Araszkiewicz Aleksandra
(A)
Banach Agnieszka
(B)
Banecka Bożena
(B)
Baranowska-Jaźwiecka Anna
(BJ)
Beń-Skowronek Iwona
(BS)
Bielec Urszula
(B)
Bołdys Ewelina
(B)
Bossowski Artur
(B)
Bury Anna
(B)
Charemska Dorota
(C)
Chobot Agata
(C)
Chojnacka Joanna
(C)
Chrzanowska Joanna
(C)
Ciechanowska Marta
(C)
Ciemięga Anna
(C)
Cypryk Katarzyna
(C)
Czerniawska Elżbieta
(C)
Deja Grażyna
(D)
Domagała Barbara
(D)
Dżygało Katarzyna
(D)
Fichna Piotr
(F)
Florys Bożena
(F)
Gawrecki Andrzej
(G)
Głowińska-Olszewska Barbara
(GO)
Górska-Flak Karolina
(GF)
Grochowska Beata
(G)
Groele Lidia
(G)
Grottel Ewa
(G)
Hogendorf Anna
(H)
Ilkowska Magdalena
(I)
Jabłońska Jolanta
(J)
Jałowiec Irena
(J)
Jarosz-Chobot Przemysława
(JC)
Jastrzębska Justyna
(J)
Kącka Anna
(K)
Kieć-Wilk Beata
(KW)
Klocek-Kopacz Mariola
(KK)
Klonowska Bożenna
(K)
Klupa Tomasz
(K)
Koch Ewa
(K)
Krętowski Adam Jacek
(KA)
Kuderska Maria
(K)
Kuśmierczyk Hanna
(K)
Kuzaka Milena
(K)
Lejk Agnieszka
(L)
Lisowicz Lucyna
(L)
Łukaszewska Barbara
(Ł)
Majcher Anna
(M)
Małecki Maciej
(M)
Małek Jadwiga
(M)
Matejko Bartłomiej
(M)
Mazur Artur
(M)
Menżyk Tomasz
(M)
Mianowska Beata
(M)
Michalak Arkadiusz
(M)
Mikietyńska Urszula
(M)
Myśliwiec Małgorzata
(M)
Nazim Joanna
(N)
Noczyńska Anna
(N)
Nowak Irena
(N)
Olech Bożena
(O)
Olszewska Anna
(O)
Ostapiuk Jadwiga
(O)
Pawełczak Stanisław
(P)
Peczyńska Jadwiga
(P)
Piątkowska Ewa
(P)
Piekarski Robert
(P)
Pietrzak Iwona
(P)
Pilecki Olgierd
(P)
Przewoźniak Sabina
(P)
Rak Sławomir
(R)
Robak-Kontna Katarzyna
(RK)
Rogalińska Marzena
(R)
Roztropowicz-Honka Anna
(RH)
Salmonowicz Barbara
(S)
Saryusz-Wolska Małgorzata
(SW)
Seifert Monika
(S)
Silkowska Elżbieta
(S)
Skotarczyk-Kowalska Elżbieta
(SK)
Skowrońska Bogda
(S)
Stankiewicz Witold
(S)
Steifert Monika
(S)
Stępień Hubert
(S)
Szadkowska Agnieszka
(S)
Szalecki Mieczysław
(S)
Szczepańska Anna
(S)
Szmigiero-Kawko Małgorzata
(SK)
Szor Katarzyna
(S)
Sztangierska Beata
(S)
Szymańska Elektra
(S)
Szypowska Agnieszka
(S)
Świderska Danuta
(Ś)
Świercz Anna
(Ś)
Tabor Aleksandra
(T)
Trippenbach-Dulska Hanna
(TD)
Trościanko Paulina
(T)
Urbańska-Kosińska Małgorzata
(UK)
Wajda-Cuszlag Małgorzata
(WC)
Witek Przemysław
(W)
Witkowski Daniel
(W)
Włodarska Marzena
(W)
Wolnik Bogumił
(W)
Wójcik Krystyna
(W)
Wysocka-Łukasik Beata
(WŁ)
Wysocka-Mincewicz Marta
(WM)
Zacharczyk Ewa
(Z)
Zarębska Joanna
(Z)
Zawodniak-Szałapska Małgorzata
(ZS)
Zmysłowska Agnieszka
(Z)
Zozulińska-Ziółkiewicz Dorota
(ZZ)
Zubkiewicz-Kucharska Agnieszka
(ZK)
Żurawska-Kliś Monika
(ŻK)
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
Nathan DM, Cleary PA, Backlund J-YC, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-2653.
Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40(12):1631-1640.
Matuleviciene-Anängen V, Rosengren A, Svensson A-M, et al. Glycemic control and excess risk of major coronary events in persons with type 1 diabetes. Heart. 2017;103(21):1687-1695.
Bebu I, Schade D, Braffett B, et al. Risk factors for first and subsequent CVD events in type 1 diabetes: the DCCT/EDIC study. Diabetes Care. 2020;43(4):867-874.
Foster NC, Beck RW, Miller KM, et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018. Diabetes Technol Ther. 2019;21(2):66-72.
Anderzén J, Hermann JM, Samuelsson U, et al. International benchmarking in type 1 diabetes: large difference in childhood HbA1c between eight high-income countries but similar rise during adolescence-a quality registry study. Pediatr Diabetes. 2020;21(4):621-627.
Jarosz-Chobot P, Polańska J, Myśliwiec M, et al. Multicenter cross-sectional analysis of values of glycated haemoglobin (HbA1c) in polish children and adolescents with long-term type 1 diabetes in Poland: PolPeDiab study group. Pediatr Endocrinol Diabetes Metab. 2012;18(4):125-129.
Szadkowska A, Michalak A, Chylińska-Fra Tczak A, et al. Achieving target levels for vascular risk parameters in polish school-age children with type 1 diabetes - a single center study. J Pediatr Endocrinol Metab. 2018;9636:1-7. https://doi.org/10.1515/jpem-2018-0098
Gawrecki A, Araszkiewicz A, Szadkowska A, et al. Assessment of safety and glycemic control during football tournament in children and adolescents with type 1 diabetes-results of GoalDiab study. Pediatr Exercise Sci. 2019;31:1-7. https://doi.org/10.1123/pes.2018-0264
Matejko B, Kukułka A, Kieć-Wilk B, Stąpór A, Klupa T, Malecki MT. Basal insulin dose in adults with type 1 diabetes mellitus on insulin pumps in real-life clinical practice: a single-center experience. Adv Med. 2018;2018:1-5. https://doi.org/10.1155/2018/1473160
Kułaga Z, Litwin M, Tkaczyk M, et al. Polish 2010 growth references for school-aged children and adolescents. Eur J Pediatr. 2011;170(5):599-609.
Craig ME, Pillay K, Hofer SE, et al. ISPAD clinical practice consensus guidelines 2018: glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. Pediatr Diabetes. 2018;19(July:105-114. https://doi.org/10.1111/pedi.12737
American Diabetes Association. 6. Glycemic Targets Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(suppl 1):S55-S64.
Diabetology C. 2018 guidelines on the management of diabetic patients. A position of diabetes Poland. Clin Diabetol. 2018;7(1):1-90.
Addala A, Auzanneau M, Miller K, et al. A decade of disparities in diabetes technology use and HBA1c in pediatric type 1 diabetes: a transatlantic comparison. Diabetes Care. 2021;44(1):133-140.
Fornari E, Piona C, Rabbone I, et al. Cardiovascular risk factors in children and adolescents with type 1 diabetes in Italy: a multicentric observational study. Pediatr Diabetes. 2020;21(8):1546-1555.
Gerhardsson P, Schwandt A, Witsch M, et al. The SWEET project: 10-year benchmarking in 19 countries worldwide is associated with improved HbA1c and increased use of diabetes technology in youth with type 1 diabetes. Diabetes Technol Ther. 2021;10:491-499. https://doi.org/10.1089/dia.2020.0618
Van Loocke M, Battelino T, Tittel SR, et al. Lower HbA1c targets are associated with better metabolic control. Eur J Pediatr. 2021;7:1513-1520. https://doi.org/10.1007/s00431-020-03891-2
Šumník Z, Pavlíková M, Pomahačová R, et al. Use of CGM and its association with type 1 diabetes control in children over the first three years of reimbursement approval: population data from the ČENDA registry. Pediatr Diabetes. 2021;3:439-447. https://doi.org/10.1111/pedi.13184
Carlsen S, Skrivarhaug T, Thue G, et al. Glycemic control and complications in patients with type 1 diabetes - a registry-based longitudinal study of adolescents and young adults. Pediatr Diabetes. 2017;18(3):188-195.
Conway B, Miller RG, Costacou T, et al. Temporal patterns in overweight and obesity in type 1 diabetes. Diabet Med. 2010;27(4):398-404.
Michalak A, Gawrecki A, Gałczyński S, et al. Assessment of exercise capacity in children with type 1 diabetes in the Cooper running test. Int J Sports Med. 2018;40(2):110-115. https://doi.org/10.1055/a-0805-1326
Pala L, Dicembrini I, Mannucci E. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials. Acta Diabetol. 2019;56(9):973-980.
Steineck I, Cederholm J, Eliasson B, et al. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18 168 people with type 1 diabetes: observational study. BMJ. 2015;350:1-9. https://doi.org/10.1136/bmj.h3234
Šoupal J, Petruželkov L, Grunberger G, et al. Glycemic outcomes in adults with T1D are impacted more by continuous glucose monitoring than by insulin delivery method: 3 years of follow-up from the comisair study. Diabetes Care. 2020;43(1):37-43.
Cardona-Hernandez R, Schwandt A, Alkandari H, et al. Glycemic outcome associated with insulin pump and glucose sensor use in children and adolescents with type 1 diabetes. Data from the international pediatric registry SWEET. Diabetes Care. 2021;44(5):1176-1185. https://doi.org/10.2337/dc20-1674
Miller KM, Beck RW, Bergenstal RM, et al. Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. Diabetes Care. 2013;36(7):2009-2014.
Araszkiewicz A, Bandurska-Stankiewicz E, Budzyński A, et al. 2020 guidelines on the manageent of diabetic patients - a position of diabetes Poland. Clin Diabetol. 2020;9(1):1-101.
Povlsen L, Olsen B, Ladelund S. Diabetes in children and adolescents from ethnic minorities: barriers to education, treatment and good metabolic control. J Adv Nurs. 2005;50(6):576-582.
Moore JM, Snell-Bergeon JK. Trajectories of hemoglobin A1c and body mass index z-score over four decades among 2 to 18 year olds with type 1 diabetes. Pediatr Diabetes. 2019;20(5):594-603.
Braun M, Tomasik B, Wrona E, et al. The stricter the better? The relationship between targeted HbA1c values and metabolic control of pediatric type 1 diabetes mellitus. J Diabetes Res. 2016;2016:5490258. https://doi.org/10.1155/2016/5490258
Birkebaek NH, Drivvoll AK, Aakeson K, et al. Incidence of severe hypoglycemia in children with type 1 diabetes in the Nordic countries in the period 2008-2012: association with hemoglobin A1c and treatment modality. BMJ Open Diabetes Res Care. 2017;5(1):e000377.
Cherubini V, Rabbone I, Lombardo F, Mossetto G, Orsini Federici M, Nicolucci A. Incidence of severe hypoglycemia and possible associated factors in pediatric patients with type 1 diabetes in the real-life, post-diabetes control and complications trial setting: a systematic review. Pediatr Diabetes. 2019;20(6):678-692.
Pedersen-Bjergaard U, Thorsteinsson B. Reporting severe hypoglycemia in type 1 diabetes: facts and pitfalls. Curr Diab Rep. 2017;17(12):131-131.
Haynes A, Hermann JM, Clapin H, et al. Decreasing trends in mean HbA1c are not associated with increasing rates of severe hypoglycemia in children: a longitudinal analysis of two contemporary population-based pediatric type 1 diabetes registries from Australia and Germany/Austria between 1995. Diabetes Care. 2019;42(9):1630-1636.
Laffel LM, Kanapka LG, Beck RW, et al. Effect of continuous glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes: a randomized clinical trial. JAMA. 2020;323(23):2388-2396.
Messer LH, Tanenbaum ML, Cook PF, et al. Cost, hassle, and on-body experience: barriers to diabetes device use in adolescents and potential intervention targets. Diabetes Technol Ther. 2020;22:1-26. https://doi.org/10.1089/dia.2019.0509
Mianowska B, Fendler W, Szadkowska A, et al. HbA1c levels in schoolchildren with type 1 diabetes are seasonally variable and dependent on weather conditions. Diabetologia. 2011;54(4):749-756.
Wielicka M, Neubauer-Geryk J, Brandt-Varma A, Myśliwiec M, Bieniaszewski L. Skin microvascular circulation is not affected by diabetes duration in young patients with non-complicated type 1 diabetes mellitus. Pediatr Endocrinol Diabetes Metab. 2019;25(4):183-187.